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Abstract 
We draw on findings from qualitative interviews with health data researchers, GPs and citizens who 
opted out from NHS England’s care.data programme to explore controversies and negotiations around 
data sharing in the NHS. Drawing on theoretical perspectives from science and technology studies, we 
show that the new socio-technical, ethical and economic arrangements were resisted not only on the 
basis of individual autonomy and protection from exploitation, but also as a collective effort to protect 
NHS services and patient data. We argue that the resulting opt-outs were a call for more personal 
control over data uses. This was not because these citizens placed their personal interests above those 
of society. It was because they resisted proposed arrangements by networks of stakeholders, not seen 
as legitimate, to control flows and benefits of NHS patient data. Approaching informed consent this 
way helps us to explore resistance as a collective action for influencing the direction of such big data 
programmes towards the preservation of public access to healthcare as well as the distribution of 
ethical decision-making between independent, trustworthy institutions and individual citizens.       
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Introduction 
Data-based research from electronic health records (EHRs) has been growing steadily in the UK for 
more than two decades (Vezyridis and Timmons 2016a). After substantial investments in clinical 
information systems across the NHS, academic and governmental research databases (e.g. CPRD, 
THIN, QResearch, ResearchOne, CALIBER) are exploiting this data for epidemiological, 
pharmaceutical and health services research.  
The UK government announced (in 2013) its own programme called ‘care.data’. Led by NHS England 
and the Health and Social Care Information Centre (HSCIC, now NHS Digital), its aim was to collect, 
de-identify and link, in one central database, clinical and administrative datasets across the NHS and 
social services (Taylor 2014) for various uses, including research. However, due to a public outcry, 
which resulted in approximately 1.5m opt-outs, the programme never fully materialised and was 
eventually terminated in 2016 after the National Data Guardian’s (NDG) review (Lea 2016). 
Care.data’s failure has been attributed to poor communication, security risks and ambiguous 
information governance and data dissemination practices (HSCIC 2014, Vezyridis and Timmons 
2017). Similar national programmes, for example in Denmark (Wadmann and Hoeyer 2018), are also 
under attack for their opaque dissemination practices in support of governmental and commercial 
contexts of exploitation. 
With the exception of some patient populations, the public seems to be largely supportive of health 
data sharing for research (Aitken et al. 2016), but at the same time confused and sceptical when it 
comes to claims of public benefit, transparency, anonymisation and consent, especially for commercial 
purposes (Castell and Evans 2016). The public is largely unaware of how its data is being used (Hill et 
al. 2013) by corporations and state agencies, often without clear public benefits (Aitken et al. 2016).  
Most of the literature has focused on public or healthcare professional attitudes to health data sharing, 
but not on analysing these two groups together, or involving the researchers who are using these 
datasets. More studies, focusing specifically on patients-citizens who have opted out, are needed 
(Rosenbloom et al. 2013) as well as studies on the public’s acceptance of ‘authorisation’ – 
institutional decision-making for data releases without informed consent – as a data governance 
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mechanism (Aitken et al. 2016). This research was designed to address these gaps, particularly for 
national data sharing programmes in healthcare by focusing on three groups involved in care.data: 
health data researchers, General Practitioners (GPs) and citizens who have opted out from, or have 
campaigned against the programme. We do this by applying an Actor-Network Theory (ANT) (Latour 
1988) approach to ask; what did resistance to care.data elucidate on how data from electronic health 
records could be exploited as a public good? What could be the role of opt-outs from big data 
programmes in the context of national health systems? 
ANT is a set of methodological tools to explore the social as a heterogeneous entanglement of ever-
stabilising and proliferating associations between human and nonhuman entities (Latour 1988). ANT 
has been used to study ethical controversies in biomedical innovation and research (Williams-Jones 
and Graham 2003, Hayden 2007, Gardner and Webster 2017, Heeney 2017). Rather than studying 
moral frameworks from idealist viewpoints, it explores the practices of doing ethics within the 
material-semiotic networks, without making value judgements and by being attentive to the ontologies 
and normativities involved in mundane practices (Mol 2013). Previously we examined the scientific 
impetus and rationale for exploiting NHS patient datasets (Vezyridis and Timmons 2016a), the state’s 
technolegal facilitation of decontextualised NHS patient data movements (Vezyridis and Timmons 
2017) and the design affordances of the opt-out form (Vezyridis and Timmons 2016b). Here we focus 
our analysis on ‘the dark side of the translation process and the disruption of the actor-network’ (Galis 
and Lee 2014: 155) to understand how concerned citizens understand and practice ethics, politics and 
dissidence via the opt-out. We do not do this in isolation but in relation to the other protagonists 
(Latour 1988) of this hybrid controversy (GPs and health data scientists) who are directly involved in 
the collection and analysis of NHS patient data and are also affected by the opt-outs. By avoiding 
linear and deterministic macro-sociological examinations of adoption and acceptance of 
technoscientific innovations, which often ignore complex power relationships, the emphasis here is on 
the (in)visible sociomateriality of this assemblage in the context of deliberative politics (de la 
Bellacasa 2011, Welsh and Wynne 2013). There are varied reasons for patients-citizens to opt out 
from big data programmes and we do not attempt to present an exhaustive list. Rather, we are 
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concerned with collective forms of resistance and how the opt-outs are ‘enacted’ (Mol 2002) here and 
now as one effect of controversial entanglements of ethical, social, political, economic and scientific 
practices; away from simplistic debates over altruism vs. egoism and closer to questions of 
(re)distributions of power and benefits. 
Power and ethics for data movements 
Science and Technology Studies (STS) has produced an extensive set of analytical tools to 
demonstrate a situated, relational and performative understanding of power dynamics and their ethics 
(Galis and Lee 2014) in the making of technological projects and scientific knowledge. For example, 
Callon’s (1984) notion of ‘translation’ has been widely used to analyse sociotechnical processes of 
bringing together and forming stable material-semiotic networks of associated human and non-human 
actors responsible for the launch and maintenance of a technological innovation. STS emphasises that 
the fate of technoscientific projects is often unpredictable, and always contingent on power struggles 
weakening or strengthening network ties. These power struggles align interests and values and, thus 
negotiate and delimit, against many other possibilities (Williams-Jones and Graham 2003), ‘the 
identity of actors, the possibility of interaction and the margins of manoeuvre’ (Callon 1984: 203). In 
his review of approaches to power, Law (1991) argues that stable sociotechnical networks are the 
relational outcome of power balances (‘power storage’) where the actors involved have either accepted 
the new power dynamics or are able to exercise their own ‘power/discretion’. In this line of ANT 
research, Latour (2004b) considers translation as the (political) process of resolving the ‘matters of 
concern’ amongst enrolled actors so as to render the resulting technoscientific assemblage a hard-to-
refute ‘matter of fact’, while for de la Bellacasa (2011) it is about actors being able to ‘care’ for the 
things they are not only materially and ethico-politically but are also affectively concerned with 
(Latour 2004b).  
Thus, a programme like care.data is theorised (in this paper) as a political performance full of tensions 
around possibilities of data exploitations and ‘different ways of doing the good’ (Mol 2002: 176). The 
paper critically questions what (and how) actors attempt to become the ‘obligatory passage points’ 
(OPPs) (Callon 1984) for the ‘decontextualization, dissociation and detachment’ (Callon 1998: 19) of 
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NHS patient datasets to increase circulations (Leonelli 2016) within and beyond the network of public 
healthcare. The paper also highlights how ontologically and normatively multiple (Mol 2002; 2013) 
datasets and data subjects come into being, as they are framed (Callon 1998) and scripted (Akrich 
1992) by scientific, governmental or corporate ‘centres of calculation’ (Latour 1988). As such, 
care.data provided the opportunity to examine not only the infrastructures and calculations attempted 
between actors (Callon 1998) for big data exploitations in public healthcare but also how (public) 
values are prioritised, stabilised or obscured (Gitelman 2013) as they are hybridised in programmes 
that blur the borders ‘between science and politics, culture and technology, morals and economy’ 
(Venturini 2010: 265).  
For this, STS scholars’ understanding of publics and their values regarding power struggles between 
actors, as they set boundaries and facilitate intersections, (Dussauge et al. 2015, Montgomery 2017) 
are of importance to this paper. Rather than being self-evident or universal, values are theorised here 
as things made in practice (Leonelli 2016, Dussauge et al. 2015) which are meaningful only within the 
networks in which they are enacted (West and Davis 2011). While for Marres (2005) publics are 
‘ungraspable’ and abstract entities, they are nevertheless formed by actors who gather together in 
‘democratic collectives’ (Latour 2004a) to evoke pressure and negotiate their participation in 
boundary-making practices (Jasanoff and Kim 2009). In light of this, it could be argued that a public 
that has opted out from care.data did not necessarily pre-exist, but it was formed to respond (as Welsh 
and Wynne (2013) would argue) to any colonisations of meanings, matters of concern and values by 
particular (institutional) ‘spokespersons’ who sought to represent this public (Callon 1984). We thus 
highlight the inscriptions, power relationships and normativities that the opt-out mediated between the 
actors associated with this controversial big data programme.    
Methods 
The paper draws on the findings of a qualitative study carried out in 2016. Data were mainly collected 
through semi-structured interviews with three groups: primary EHR data researchers (n=11), GPs 
(n=7) and citizens (n=9) who had opted out from or campaigned against care.data. Participants (10 
female and 17 male) were relatively older and well-educated. Researchers interviewed were working 
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at the academic research databases mentioned previously, in roles including statistics, epidemiology, 
data architecture, administration, and research analysis. For the GPs, areas of expertise included 
clinical commissioning, data protection, ethics and academic health data-based research, while for 
citizens and campaigners their expertise included: information governance, business analysis, (non-) 
academic research, social work and public healthcare. Findings are also informed by observations at 
the organisations studied and from attending team meetings, conferences, public consultations and 
courses on conducting research with data from GP records. 
Participant recruitment was completed via: (for citizens) social media (#caredata) and newsletters to a 
patient advocacy group (Healthwatch); (for researchers) targeted emails; (for GPs) targeted emails and 
bulletins. All the digitally audio recorded and anonymised interviews were conducted by the first 
author in 2016 via face-to-face (n=16), phone (n=10) and Skype (n=1) and lasted between 20 and 113 
min (average duration 55 min). Following a constructivist grounded theory approach (Bryant and 
Charmaz 2007), data was analysed inductively, using QSR NVivo 11, to identify differences, 
relationships and patterns among participants’ narratives, and construct the conceptual understanding 
of their important meanings faithfully, inclusively and contextually. The study obtained ethical 
approval from Nottingham University Business School REC. 
Findings 
Resisting exclusion from public good management 
The study found support for the principle of re-using large conglomerations of personal health data for 
wider societal benefit. However, the potential value of these datasets translated by care.data as 
‘matters of fact’ (Latour 2004b) for the improvement of health (and wealth) included a prescriptive 
policy normativity of exclusion of patients-citizens and GPs from co-shaping the exploitation of this 
public good (Jasanoff and Kim 2009, Welsh and Wynne 2013). The attempt by the programme’s 
leaders to black-box the aggregation and assetisation of NHS patient datasets via an ‘all or nothing’ 
approach to informed consent (see also Vezyridis and Timmons 2017) and their limited engagement 
with public deliberation destabilised the hybrid (Latour 2004b). The ‘illegal and completely cavalier 
way’ (Citizen 11) care.data was to deal with their personal health data, and with the mandatory 
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extractions for GPs raised individual and societal concerns (Latour 2004b) around the construction of 
values and entanglements of NHS patient datasets within and beyond public healthcare. 
..at some point I might opt back in, it’s not that I’m against the principle, I just don’t think [the 
programme’s leaders] have got it right yet. (Citizen 1) 
.. most people are altruistic, put up a good suggestion and you'll get cooperation, but if you 
come in all heavy-handed and say, we are going to, because we can, you're going to get 
resistance… what [programme’s leaders] said was, we're going to use it for economic 
regeneration and we're not going to ask you first. (GP 1) 
With its lack of tiered consent for patients-citizens, and without any meaningful choice about potential 
uses and users of NHS patient data (see also Sterckx et al. 2016), the opt-out attempted to inscribe in 
this network an unacceptable amplification of power asymmetries. By transferring rights of (obscured) 
exploitations to certain institutions, this ‘interessement’ device (Latour 1988) of (inadequate) personal 
control failed to enrol them, while making visible the lack of ‘power/discretion’ for the local network 
to participate actively in decision-making. Data transmissions were irrevocably destabilised (Law 
1991), as some GPs and members of the public were seeking reassurances that these datasets would 
facilitate what they considered socially responsible research for public benefit, rather than 
appropriating and restricting access to these datasets for personal benefit (cf. Sterckx et al. 2016).  
I think everybody wants the ability to say, I feel good about donating it because I know what's 
happening to it … But if that organisation then says, ‘you don't have a say in how we spend 
your money’, then you're not going to give them the money. (GP 2) 
I would like to understand better who’s going to benefit from it. So, if it’s in the public 
interest …, I would always say yes … I wouldn’t necessarily be happy that any information I 
gave would be able to be used by any researcher; for example, if a company was then going to 
buy my data and restrict the use of that information … because they were then going to be 
able to make a big profit from it … I would want to understand what would that mean for that 
drug company if they profit by using the information in Britain, but they can’t get that same 
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information in developing countries … are you then encouraging drug companies to only 
research … first world countries’ problems? (Citizen 2) 
In effect, the opt-out was translated as an ethical, political and affective rendering and used as an 
active commitment in mediating responsible data exploitations (de la Bellacasa 2011) by restoring 
power imbalances (Latour 1988). The programme could then be reconfigured to address these 
citizens’ matters of concern and care, rather than just protecting themselves at the expense of the 
society at large (cf. Sterckx et al. 2016). The attempt to place data exploitations in a transactional 
narrative where data extractions to the state, in exchange for NHS services, bifurcated research and 
care. This prioritised data collections and exploitations at the expense of the local relationships that 
produce the data (Montgomery 2017). The use of the NHS was understood as an absolute entitlement 
of citizenship, independent of any other obligation, and there was a material and affective attachment 
to the NHS (de la Bellacasa 2011). The attempted enactment of a new reality (and normativity) (Mol 
2002) in the use of NHS services as an indistinguishable entanglement of healthcare provision, 
participation in data-based research and wealth creation, also shifted responsibility for maintenance 
from institutions to supportive individuals and publics (see also Marris 2015). This was perceived as 
‘a really radical change to the social contract that we have in this country’ (Citizen 3).  
… it is another sneaky manoeuvre that makes me lose confidence in the ethics of this 
programme … We have the right to privacy and confidentiality which means we have the 
right to exercise it without being shamed for it. And I think a lot of the people who have opted 
out would be inclined to opt in if their concerns about confidentiality and ethics were 
addressed. That's not freeloading, that's just being sensible. (Citizen 4) 
… but there are all sorts of more objectionable ways that people get free rides at the moment. 
We don’t deny transplants to people that don’t carry a donor card, and I would argue that 
that’s a much worse kind of free ride. (Researcher 1) 
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Enforcing transparency, accountability and trustworthiness 
The care.data controversy also opened up the black-box of data extractions and releases. Matters of 
concern around (information) governance, agreements with obscure actors, assetisations,  
accountability and oversight were exposed and challenged, revealing complex and dynamic 
relationships that refused reductions. Socio-material practices of data exploitations, political and 
economic asymmetries between data producers and users, prioritisations and stabilisations of ethical 
and economic values were all rendered visible and scrutinised for accuracy and conflicts of interest. 
Publicity campaigns, particularly via ‘junk mail’ methods, were deemed unsatisfactory (cf. Hays and 
Daker-White 2015). Citizens perceived as distorted NHS England’s claims of completely adequate 
data security and that no unintended harms would be caused by the proposed centralisation of all 
personal health data into one database. Confusing vocabularies and terminologies around data(bases) 
in the public debate excluded concerned citizens further from problematising and defining (Galis and 
Lee 2014) what is public and what is private, or good and bad uses. For policy-makers, care.data was 
only an issue of public acceptability and a question of which communication strategy about benefits 
could help the public overcome its ‘privacy paranoia’ and ‘free riding’, so as to manage the 
controversy away from more inclusive NHS patient data exploitations for public benefit (cf Marris 
2015). 
What everybody’s frightened of is that if people ever were asked to opt in, a lot of them 
wouldn’t. (Researcher 1) 
[Programme’s leaders] have used those terms interchangeably as if there's no difference like 
opt out and various terms like, pseudonymised, anonymous, these terms have, in my view, 
purposefully been misused and used interchangeably to try to prevent debate and to try to 
paint anyone who raises criticisms as a conspiracy theorist. Because they're using terms that 
are meaningless. (Citizen 3) 
The report by the Institute of Actuaries (Banthorpe et al. 2013) on accurate health insurance pricing, 
based on the analysis of hospital data provided by HSCIC, and the review of all NHS patient data 
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releases that followed (HSCIC 2014) had been instrumental in raising public anxiety about data 
disseminations.  
These publications constituted an ‘ethical moment’ (Heeney 2017) that brought to the fore not only 
questions about the normative framework and institutional practices of data releases but also decisions 
to opt out. They made visible not only the incongruity between the programme’s stated aims and 
actual practices of the institution responsible for these datasets, but also unknown relationships 
between various ‘centres of calculation’ (Latour 1988) and the NHS already operating in the 
background. Concerned about unknown multiplications of their medical histories and exploitation by 
different interrelated actor-networks (Mol 2002) beyond public healthcare, these members of the 
public lost their trust in the programme before any actual harms materialised: 
And care.data is not necessarily egregiously different to anything else, but it’s the straw that 
broke the camel’s back … The fire storm around care.data was only partially about care.data. 
A lot of it was what do you mean they are already selling hospital data? The reason everybody 
was so outraged about care.data was when the NHS said this is what we’ve been doing for 25 
years, people said, what do you mean, this is what we’ve been doing for 25 years? (Citizen 5) 
..when it came to care.data [Patient Participation Group members] were angry because they 
felt a betrayal of trust, … that their records were being taken and they were being told that it 
was for scientific purposes when actually the government were selling it on. They were fearful 
that insurance companies could actually access their individual record, without permission. 
(GP 3) 
Although the researchers interviewed considered information governance procedures in the NHS as 
strict, to the extent that they restricted ‘worthwhile’ research, they nonetheless believed that it was 
important for them to be strict so that data did not get into the ‘wrong hands or isn’t used for the 
wrong purposes’ (Researcher 2). They thought that it was better to be over-cautious, especially when 
the omnishambles of care.data had already had a negative impact on their work. Others understood 
information governance not as a barrier but as a kind of “ethical data hygiene”: necessary preparatory 
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steps that researchers should take to make sure that their use of data is socially safe and ethically 
sound, ‘like washing your hands before having dinner’ (Researcher 6).  
… 5 years ago if you wanted to access any of these data sources was much … easier, the 
process now is lengthy … maybe because of care.data, but it is something that is supposed to 
be like this so … you cannot say that it made it bad, it changed it … (Researcher 5) 
..some organisations pulled out of [the database], took their consent back and it stopped us 
really being able to go out there and promote it … But it was just so stupid the way they did it, 
I mean they really did treat people as though they just had the right to do all these things. 
(Researcher 3) 
Protecting public healthcare from predatory market forces 
The care.data controversy and the resulting resistance to the proposed entanglement of science, 
technology, politics, economics and ethics for NHS patient data assetisation moved beyond the ethics 
of individual privacy and confidentiality. It called for an examination of how the proposed 
arrangements for data exploitations would continue to support other actor-networks entangled with 
this one, such as access to (public) healthcare and also responsible scientific research. Here, public 
alienation was fuelled not by profit-making per se (see also Aitken et al. 2016) but by a lack of 
transparency and engagement in deliberations about the ‘ethos of investment’ and innovation 
(Muniesa 2017, Marris 2015) from these datasets. They felt uneasy with the idea that these public 
datasets could be used by private actors to reap the economic benefits directly, without giving back to 
the country that had made them available in the first place. Interviewees thought that the concept of 
care.data was good, notwithstanding issues of communication and meaningful choice. Citizens and 
some GPs accounted for their criticism in terms of an ‘execution [that was] much too commercially 
focused and it [seemed] to be much more for the benefit of the private sector than the benefit of the 
health for people in the UK’ (Citizen 4).  
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… and the metaphor of course is the immortal life of Henrietta Lacks. So the idea that 
someone could take something made out of British healthcare records and become fabulously 
wealthy is something that grates with the average GP and patient. (GP 4) 
This is not to say that private involvement in the NHS was entirely unacceptable to participants. It was 
that making the selling of data ‘an industry [was] the wrong approach’ (Citizen 6). They refused to 
accept the attempted stabilisation of this network through a silencing of their objections as well as 
private actors obtaining more power and knowledge of the NHS than could possibly be justified 
(Callon 1984). They feared that the NHS is threatened by the introduction of a private insurance model 
that will create additional problems of access to healthcare for many. Care.data was, therefore, seen 
not as a big data scheme that will ultimately benefit people, but one that will also facilitate the demise 
of the public character of the NHS via the provision to private companies of ‘information at 
population wide level ... to be able to have enough business intelligence .. to understand how the 
system works’ (Citizen 2). Most citizens and some frontline GPs were worried that this private 
involvement was more likely to cause, rather than solve, problems that may be detrimental to the 
sustainability of the NHS (see also Montgomery 2017).   
Because I don't think there's any trust. I think you can say, giving it to these big 
pharmaceuticals, giving it to [private healthcare provider], increase the economy, but people 
say, well I don't want [private healthcare provider] to have this information, I don't want them 
to be any more better off and in a position to cause detriment to the NHS. (GP 2) 
What are big pharma using these data for? Well, they’re using them … for marketing, which 
is … objectionable. So, if they’ve got a new, expensive antidepressant that’s not being 
prescribed to certain people, they could find that out from the GP data, then adjust their 
marketing to try and cost the NHS more money. (Researcher 1) 
Such covert profit-making practices based on these data are antithetical to the founding principles of 
the NHS. Care.data was seen as a new database which would have brought together different social, 
technical and regulatory actors to form new heterogeneous networks to expand the scope of 
questionable secondary uses of data, and exert new powers through specific orderings, as one GP 
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suggested. For most participants, if any kind of exploitation was to take place, it should not be at the 
expense of the individual, whether that was advertising private healthcare, stopping welfare benefits or 
excluding patients from care.  
I wonder if new databases make new rules and new rules means the ability to do things that 
other databases might not do, like export data to other institutions, countries, private 
companies, etc. which is something that existing databases might not do. So the conspiracy 
theorist in me wonders whether this is something that’s economically driven. (GP 4) 
I don't believe that it would benefit people with chronic long-term health conditions in any 
way. I think the insurance companies will cherry pick healthy people to provide coverage to 
and people like me will be left with no healthcare or bottom of the barrel scraps of healthcare, 
like in America. (Citizen 4) 
Citizens expected that their responsibility to share their data would be matched by the responsibility of 
data users to share the NHS’s foundational values (e.g. universal care). These private actors were not 
understood as residing outside society. They are members of the same assemblage and are expected to 
continue performing the meanings and values associated with the NHS. If not, then the opt out is 
mobilised as an OPP for safeguarding the NHS and protecting its assets from unacceptable political 
and market forces (Latour 1988). 
Reclaiming responsibility from institutional decision-makers    
Care.data became a question of what kind of normativities should accompany the ontologies of 
patients-citizens, datasets, regulations and institutional decision-makers. The controversy was the 
outcome of two different ‘ontonorms’ in tension (Mol 2013). On the one hand, these members of 
society enacted the patient-citizen as a societal active subject in an accountable and mutually 
beneficial data sharing relationship with institutional decision-makers and specific data actors; on 
agreed purposes of use as well as benefits distribution. On the other hand, the patient-citizen was 
scripted (Akrich 1992), via the opt-out, as an individual passive object of data extractions by 
representative (unaccountable) institutional decision-makers. In anticipation of maximum return on 
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investment and potential wider societal benefits as well as risks of abuse, data exploitations had to be 
left fluid and open to unknown purposes.  
However, care.data, as a sociotechnical actor-network in the wider governmental network, was not 
criticised in isolation, but in relation to other, past and present, translations (Callon 1984) that lacked 
wider public and clinical support: national technology programme failures (e.g. NPfIT, SCR) (cf. Hays 
and Daker-White 2015, Greenhalgh et al. 2010) or controversial government data sharing schemes 
(e.g. Home Office, Google DeepMind) (see also Sexton et al. 2017). This entanglement not only de-
stabilised this network but, more importantly, called for the re-problematisation of NHS patient data 
exploitations as an issue of institutional trustworthiness and sociotechnical competence, necessitating 
a public to rise to the occasion (Marres 2005), take responsibility for its data and reclaim a more 
mediating, and OPP, role (Callon 1984) in decision-making about data releases. For example, some 
participants, especially those working in the NHS or in the information governance sector, expressed 
their disappointment for the fact that ‘privacy by design’ (Citizen 7) was missing from NHS patient 
data systems. Tracking responsibility, or exercising control was becoming increasingly difficult in 
public services with too many databases where the burden is always placed on citizens ‘to have to 
know them all, know where the fair processing notice is, know how to opt out’ (Citizen 1).  
It wasn’t necessarily care.data exclusively ... the rest of government is no better than the NHS 
was. We’ve seen that the rest of government is just as screwed up with data as HSCIC was 
two years ago. The problem is that people cared about the NHS more and the NHS was first. It 
was not worse. (Citizen 5) 
I don’t trust anybody with it, because I’m a Data Protection Officer, and I know what mistakes 
are made. The fact that I can no longer trust the NHS, really disappoints me, … and I would 
probably trust someone like [grocery retailer] to look after my data … because to them, it’s 
money, they can’t afford data breaches, because of their reputational damage, and the costs 
that they might incur. I think public sector people have been too lackadaisical, and have not 
realised the value of data. (Citizen 1) 
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Most citizens were not confident that they could trust institutions such as HSCIC or the Information 
Commissioner’s Office (ICO), to act as their ‘spokespersons’ (Callon 1984). For example, the current 
NDG was highly regarded by participants due to her experience in the field of information governance 
in healthcare as well as her ‘code of ethics’ (Citizen 4), but contrary to the recent NDG review (Lea 
2016) most citizens felt that some institutions’ proclaimed independence and trustworthiness had been 
compromised too many times in the past by government. Therefore, they were not ‘complacent in 
giving up individual rights to an institution’ (Citizen 2). 
… HSCIC, they have no credibility from my perspective because they're not independent … I 
think I would place my trust in [Caldicott review body] because they have raised these issues 
and Dame Fiona Caldicott has had a critical independent stance on care.data … But ideally, I 
would like to see individual patients being able to take control of their care record. (Citizen 3) 
I don't think the [ICO], for example, appears to instil a great deal of fear into corporations. I 
think they know that they are an over-stretched organisation … I just think they're not the best. 
They may have some of the sort of legal powers behind them, but I don't think they make 
much use of them, and I think what powers they have are fairly ineffectual. (GP 5) 
Unlike other programmes of data collection for scientific analyses, the stability and durability of this 
network required constant local work and maintenance from all actors involved for continuous 
extraction of patient data. The expectation was of an ongoing relationship between patients, the NHS 
and institutional decision-makers. In effect, consent did not exist a priori but it was understood as an 
ongoing relational achievement of stable socio-material relationships (Mol 2002; Leonelli 2016) 
across and beyond the NHS. Citizens were aware of the technical and financial challenges in setting 
up and maintaining these relationships. They also understood that not everyone might be sufficiently 
‘educated’ or ‘articulate’ to make informed decisions. However, they considered ‘a one size that fits 
all’ (Citizen 1) model of control and consent unsatisfactory. They would like to see a model where the 
individual has the opportunity to make a choice, while for those who do not wish to take up control 
other arrangements, such as ‘the GP to have control of that data’ (Citizen 3), can be put in place. 
Within this more collaborative governance framework, institutional experts could provide them with 
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their informed opinions about potential uses and users of their data, but it should be ‘the people with 
the final say over where their information goes’ (Citizen 9).  
Conclusion 
Care.data was a big data programme that attempted to disrupt and re-configure, unsuccessfully, the 
current epistemological, political, economic and social practices of big data-based research in 
biomedicine (Leonelli 2016). By mobilising normative assumptions about citizenship and economics 
(Woods 2016), it brought new expectations and promises (Brown 2007) of innovative research for 
capitalising NHS patient data. However, just as with other national (EHR) centralised 
implementations, it took ‘on a civic character’ (O’Doherty et al. 2011: 368) and followed an 
unpredictable path through a complex and dynamic storm of social, technical, ethical and legal 
challenges (Greenhalgh et al. 2010) translated as decisions about which material-semiotic reality 
should be made durable and visible, and which not (Strathern 2000).   
We used an ANT approach to illuminate care.data’s failure to consider the fact that any values of such 
programmes for the public good are not inherent and, therefore, accepted as given by the socio-
material networks they attempt to re-configure. They are always enacted in practice by specific 
stabilised networks against a backdrop of many other possibilities (Mol 2002). In developing one of 
the biggest healthcare databases in the world, embedded norms and values need to be translated as 
differences can be expected among ambivalent actors (Singleton and Michael 1993) who are provoked 
to react (Callon 1984). From an STS perspective, care.data can be described as a typical example of an 
imposed ‘sociotechnical imaginary’ (Jasanoff and Kim 2009) that for sceptical voices was more of an 
institutional reassurance of self-acquired ethical legitimacy. It failed to engage with the full 
sociomateriality of NHS patient datasets and, failed to consider (in public deliberation and policy-
making) all matters of concern, entanglements of values (Dussauge et al. 2015), affective attachments 
from, and invisible work by, those who care for the production of the data (de la Bellacasa 2011). 
Therefore, it could not develop collectively a wider common vision and practice for data exploitations 
by debating the extent to which (and by whom) the marketisation of datasets and the public good will 
coincide (Gardner and Webster 2017). 
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Data research charities and institutions, private companies and government departments failed to 
eliminate the stark contrast between a ‘regime of hope’ (Moreira and Palladino 2005, Brown 2007) for 
speculative investments in scientific discoveries in the future and a ‘regime of truth’ where, for some 
of our participants, the risks of data exploitations, knowledge monetisation and the privatisation of 
NHS services were already evident. By focusing too much on raising awareness of the scientific value 
of these datasets, which none of our participants rejected in principle, they failed to reach consensus 
about other important ‘matters of concern’ (Latour 2004b). A convincing discourse and practice, for 
example, in support of the public character of NHS services or how these datasets would be protected 
from profitable ‘closed-data and closed-algorithm business models in health’ (Wilbanks and Topol 
2016: 347) was missing.  
The programme aimed at securing the bare minimum of trust while maximising potential returns on 
investment. It thus quickly dismissed privacy and respect for individual autonomy as individualistic 
rights opposing wider prosperity, rather than seeing them as principles of social trust and public 
engagement (Taylor 2014). The rigidness of the programme’s design and the ‘blurring of the 
distinction between ownership of technical innovation and ownership of information’ (Munns and 
Basu 2013: 130-131) propagated the ‘myth’ of a paranoid public of free riders. At the same time, 
shifts in alliances between the NHS, patients-citizens and unknown future users (Zuboff 2015) of these 
datasets were taking place beyond the context of public healthcare. In that respect, the care.data 
controversy was also about ‘about power, both power over data and power over the outputs data can 
produce’ (Taylor 2016: 11). It was about choice with regards to the kinds of logics and subsequent 
entanglements of exploitation in which concerned citizens, GPs and even health data researchers were 
expected to enrol (Callon 1984) without any ‘spaces of contestation’ (Barry 2002: 270).  
The programme instilled in parts of the public a sense that it was a politically and economically driven 
project, rather than a clinical-scientific one that would benefit patients-citizens (Greenhalgh et al. 
2010). The opt-out was the materialisation of critique, protection and distrust towards institutional 
representatives and designers of such programmes (Greenhalgh et al. 2010) that extended ‘beyond 
individual modes of opting out to collective forms of conscientious objection’ (Benjamin 2016: 968). 
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It was a material and affective commitment by dissenters to mediate between prescriptive and 
exclusionary science and policy normativities (Jasanoff and Kim 2009, Welsh and Wynne 2013) and 
affirm that these datasets are utilised for wider public benefit, with minimal social and economic harm 
for patients-citizens. As such, it was an ethical, social, political and economic collective activity 
against a “conscripted marketisation” of NHS patient data. Personal responsibility and control were 
mobilised as a way for the public to maintain its OPP role (Callon 1984) for secondary data uses as 
well as for adequate representation of the public’s interests and values (Gottweis et al. 2011) when it 
comes to the distribution of public benefits (Benjamin 2016). In effect, it moved the discussion from 
the ethics of public altruism to questions around loyalty to NHS and, the trustworthiness and 
transparency of people and practices behind such programmes to represent public interests and values 
(Zuboff 2015).  
As Winickoff (2016: 54) argues ‘benefit sharing attempts to stitch a distributive norm at the seam of 
the market and gift economies’. It calls for both distributive justice and power (O’Doherty et al. 
2011), away from individualistic understandings of autonomy and protection (Dove et al. 2017). In 
this way, we can begin exploring ways of including in governance structures (of national big data 
programmes) ‘the collectivity as sovereign ethical subject’ (Hayden 2007: 744). We can then develop, 
for example, a ‘partnership governance’ (Winickoff 2016) that goes beyond occasional public 
consultations, to provide them with opportunities to co-configure public meanings, risks and values of 
these datasets (Jasanoff and Kim 2009), co-formulate governance policies (cf. Dove et al. 2012) and 
exert a share in decision-making on how best to distribute the benefits they have co-produced 
(Winickoff 2016). These would be based on mutually agreed boundaries of data exploitations and 
standards of responsive accountability (Welsh and Wynne 2013). 
Based on our findings (and the fate of care.data) we suggest that choice should be supported to act as 
the necessary ‘mediator’ (Latour 1988) that could bring this material-semiotic network together. As de 
la Bellacasa (2011) would assert, establishing and maintaining the technoscientific assemblage of a 
national healthcare database should not be about deprecating concerns, distorting agendas (Galis and 
Lee 2014) or excluding from translations those who disagree with it, based on binary (moral and 
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epistemological) understandings of caring (or not) to ‘save lives’. If treated as a collective action in the 
context of deliberative politics (Welsh and Wynne 2013), choice could act as, for example, a 
barometer of ‘social acceptability’ (Floridi and Taddeo 2016) for big data programmes in healthcare – 
not only the ethical right of the public but also a distributed form of enforced public awareness, 
accountability, oversight and social responsibility.  
In a political-economic environment where a clear determination of ‘public interest’ is lacking, 
growing commercial interests are increasingly structured around proprietorial control of such data 
assets (Taylor 2016) and the knowledge produced for the financialisation of biomedicine (Birch 2017). 
Data collections are increasing in size and scope across and beyond healthcare, while public 
confidence in privacy protection is reducing (Phillips et al. 2017). Simultaneously, shared decision 
making between clinicians and patients is promoted to move from a paternalistic to a more patient-
centred model of communication (Spatz et al. 2016). Removing a meaningful and collectively agreed 
opt-out confines data users’ relationship with the public solely to communication of benefits and 
assurances of sufficient data protection practices (cf Lea 2016). This may result in another form of 
(data) paternalism and a ‘governance by elites’ (Woods 2016) model of NHS patient data use where 
data users and policy-makers set the usage agenda and the conditions of public research participation, 
increasing the ‘agency gap’ (Winickoff 2016). Consequently, public distrust and resistance to national 
big data programmes in healthcare grows.  
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